BPS3021 Biotechnology

How BPS3021 is assessed

What BPS3021 covers

Follow the product journey from gene design and expression to biological delivery, comparability and therapeutic function.

Its recurring skill is evidence interpretation: identify what an assay measures, locate the first failed stage and state a conclusion that does not outrun the data.

Build a comparability argument from converging analytical, functional, pharmacokinetic and targeted clinical evidence. Turn every proposed experiment into a risk, method, expected interpretation and next-decision sentence.

A biosimilar is a therapeutic biologic that is highly similar to a reference product, with no clinically meaningful differences. Biological production prevents the simple identity argument used for many small-molecule generics. The development question is therefore comparative: how much uncertainty remains after analytical, functional, pharmacokinetic and clinical evidence are read together?

clinical residual uncertaintyPK / immunogenicityfunctional bioassaysanalytical sim Distinguish association, internalisation, localisation, cytosolic access and biological function. Draw the delivery funnel and attach one assay, one valid claim and one invalid claim to every stage. A labelled therapeutic can generate a strong cell-associated signal while remaining bound to the outer membrane.

Removing or quenching extracellular fluorescence distinguishes total association from internal signal. Microscopy with compartment markers then asks where the internal material went. A cytosolic reporter or biological response is needed to show productive delivery.

associationinternalisationcorrect localisationfunctional deliveryEvery barrier removes candidates that looked successful a Design a recombinant construct from the intended protein backwards, then separate selection, screening and verification claims. Draw the entire clone to verify chain and attach one bounded conclusion to each method. Recombinant production begins long before a colony appears.

The useful mental model is a decision chain: choose a gene and vector, create compatible ends, join the insert, move the plasmid into a host, select candidate cells, then verify what each candidate actually contains. A selectable colony proves survival under the selection condition; it does not prove that the desired insert is present, correctly oriented or in frame. Start at the expression product.

The coding sequence m Choose a host from product requirements, then recover, purify and characterise the recombinant protein. Link host capability to the required product attribute, then diagnose expression, solubility, purity and function in order. Choosing an expression system is a product decision, not a race for the largest yield.

Bacteria are fast, inexpensive and easy to scale, but they do not reproduce every eukaryotic folding or post-translational modification. Yeast adds processing capacity and high productivity, while mammalian cells offer more human-like processing at greater cost and complexity. Cell-free systems offer control and rapid testing but bring their own scale and cost constraints.

A small, Match disease mechanism to expression, silencing or editing, then trace cargo to its required compartment. Answer in the order objective, cargo, destination, duration, limitations, measurements and controls. Nucleic acids can act as drugs by inducing expression, silencing a target or correcting a sequence. The biological problem determines the action.

Loss of a functional protein may motivate DNA or mRNA replacement; excess harmful protein may motivate siRNA knockdown; a defined pathogenic variant may motivate editing when the delivery and safety case is credible.

DNA → nucleusmRNA → cytoplasmsiRNA → RISCCRISPR → genomeCargo choice determines the intracellular destination and the barriers th Relate protein properties and product design to instability, distribution, clearance and patient use. Practise four links: observed failure, molecular mechanism, formulation lever and confirming assay. Therapeutic proteins do not behave like typical small molecules.

They are large, structurally delicate and vulnerable to aggregation, adsorption, oxidation, deamidation and proteolysis. Oral exposure is usually poor because the gastrointestinal tract degrades proteins and epithelial permeability is low, so parenteral routes are common. The route then shapes absorption rate, exposure and patient burden.

absorptiondistributiontarget bindingdegradationclearanceA protein's exposure reflects both f Calculate relative copy number only after assessing replicate behaviour, controls and product specificity. Write the formula, signed substitution, exponent and qualified biological conclusion as four separate lines. Quantitative PCR follows fluorescence as double-stranded DNA accumulates.

The cycle of quantification, Cq or Ct, is the cycle where fluorescence crosses a defined threshold. A lower Cq means the target crossed earlier and therefore began at a higher abundance, provided amplification efficiencies are comparable. The course uses a plasmid target and a chromosomal reference to estimate average plasmid copies per bacterial cell.

A calculation is the middle of the evidence chain, not Choose antibody format, location and assay from the intended therapeutic mechanism. For every format, state one enabling property, one trade-off and one functional assay. Therapeutic antibodies can neutralise a soluble ligand, block receptor signalling, recruit complement, engage Fc-receptor-bearing immune cells or carry a cytotoxic payload.

The first design question is the intended mechanism. A whole IgG supplies bivalency, Fc-mediated persistence and possible effector activity, but it is large, expensive to manufacture and may penetrate dense tissue poorly. Fab and F(ab')2 fragments retain binding without Fc; F(ab')2 remains bivalent. scFv molecules link variable domains in a compact engin

Worked example · free

Calculate plasmid copy number from qPCR

Key terms

Cycle of quantification

The PCR cycle at which fluorescence crosses a defined threshold; lower values indicate greater starting abundance under comparable amplification conditions.

Biosimilar

A biological medicine shown to be highly similar to a reference product with no clinically meaningful differences.

Affinity chromatography

A purification method that captures a target through a specific interaction between a tag or protein feature and an immobilised ligand.

Functional delivery

Arrival of intact cargo at the compartment where it produces the intended biological action.

Endosomal escape

Release of internalised cargo from an endosomal compartment into the cytoplasm.

Monoclonal antibody

A defined antibody product derived from one binding specificity and produced reproducibly from a controlled sequence.

Codon optimisation

Synonymous redesign of a coding sequence to improve compatibility with the expression host without changing the amino acid sequence.

Totality of evidence

An integrated comparability judgement built from analytical, functional, pharmacokinetic and other targeted evidence.

Immunogenicity

The capacity of a therapeutic product to provoke an immune response that may alter safety, activity or pharmacokinetics.

BPS3021 FAQ

Questions students ask in each BPS3021 chapter

Does antibiotic growth prove the insert is correct?

No. Growth supports uptake of a selectable plasmid, but insert identity, orientation and sequence require independent tests such as PCR, digestion and sequencing. A diagnostic sequence should preserve an independent check on insert identity and reading frame. Chapter 01 · Cloning and Vector Verification

Why not express every protein in bacteria?

Bacteria are efficient but may not supply the folding or post-translational processing required for a complex therapeutic protein. The defensible choice links host processing capability to a required product-quality attribute. Chapter 02 · Expression Systems and Protein Purification

Does lower Cq mean more starting template?

Yes under comparable assay conditions, because a more abundant target crosses the fluorescence threshold earlier. Comparable efficiency and consistent threshold placement are necessary for that directional interpretation. Chapter 03 · qPCR and Experimental Evidence

Is a biosimilar identical to its reference product?

No. The required conclusion is high similarity with no clinically meaningful differences, supported by the totality of comparative evidence. Analytical and functional comparisons determine which residual uncertainties need targeted later studies. Chapter 04 · Biosimilars and Totality of Evidence

Why are therapeutic proteins often injected?

Proteins are vulnerable to gastrointestinal degradation and usually cross epithelial barriers poorly, making reliable oral exposure difficult. Route selection follows degradation risk, permeability, exposure goals and the practical burden on patients. Chapter 05 · Protein Pharmacokinetics and Formulation

Does bright fluorescence prove delivery?

No. It can reflect surface binding, trapped material or free label; functional delivery requires compartment-specific and biological evidence. Productive function requires cargo to reach the correct compartment while remaining intact and biologically active. Chapter 06 · Cellular Delivery Barriers

Why use a whole IgG?

A whole IgG offers bivalent binding, longer persistence and possible Fc effector function when those properties fit the mechanism. Its bivalency and Fc functions must still match the intended therapeutic mechanism and safety profile. Chapter 07 · Therapeutic Antibody Design

Why does DNA face a larger delivery barrier than mRNA?

DNA must escape endosomes and reach the nucleus, while mRNA can function after productive delivery to the cytoplasm. The additional nuclear-entry requirement makes productive DNA delivery a longer intracellular journey. Chapter 08 · Nucleic Acid Therapeutics

How to study for the exam

Study each topic as an evidence chain. Rehearse one mechanism, one decisive assay, one control and one unsupported claim for every platform. Keep qPCR arithmetic visible, compare biotechnology options on explicit dimensions and finish recommendations with the next experiment that separates competing explanations.